I am struggling to understand the anger and animosity. When the smoke clears — to use a fire analogy — the fire didn’t burn anything down of significant value.
Could Dr. Missling have done a better job of communicating the endpoint change in advance and made it clear that the FDA requested it? Sure. But I doubt that would have stopped Adam Feuerstein from finding something else to criticize.
Remember back in the day when he criticized the science as a fraud? He’s changed his tune as more evidence mounts that the S1R activation has a noted effect on various CNS conditions.
Nothing has changed for the worse. Anavex has plenty of cash so it’s not like a short-term depressed share price means we’ll suffer additionally unnecessary dilution. And Adam F isn’t on the FDA advisory panel, so it doesn’t really matter what he thinks. If the FDA is okay with the revised endpoints, that’s all that matters.
Those complaining are doing so for one of three reasons: 1) they were hoping to cash out ASAP, 2) they are buying into Adam F’s narrative that A273 doesn’t work, or 3) they’re panicking because of the unrealized losses in their account.
But we’ve been through this song and dance several times since 2015 and survived, and we’ll survive again this time.
Not everyone has been in AVXL since 2015, some may have bought their shares this summer at the all-time highs and it’s natural for them to feel the same unease that we did many years back.
I’ll say it again — the only opinion about A273 that matters is the FDA’s, and so far I’ve heard nothing from the FDA to indicate that they are concerned with the trial setup. If the FDA isn’t concerned, why should I be?
News 
Market Data 
Discover 
AI
